XML 46 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
License and Collaboration Agreements (Narrative) (Detail) (USD $)
 12 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended
Jun. 30, 2012
Year
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2012
Alimera
Dec. 31, 2009
Alimera
Month
Jun. 30, 2012
Alimera
Jun. 30, 2011
Alimera
Jun. 30, 2010
Alimera
Jan. 31, 2008
Alimera
Jun. 30, 2012
Pfizer Collaboration Agreement
Jun. 30, 2011
Pfizer Collaboration Agreement
Jun. 30, 2008
Pfizer Collaboration Agreement
Jun. 30, 2011
Pfizer Collaboration Agreement Restated
Jun. 30, 2011
Pfizer Collaboration Agreement Restated
Jul. 31, 2011
Intrinsiq Materials Cayman Limited
Jul. 31, 2009
Intrinsiq Materials Cayman Limited
Sep. 30, 2011
Intrinsiq Materials Cayman Limited
Jun. 30, 2011
Intrinsiq Materials Cayman Limited
Jun. 30, 2010
Intrinsiq Materials Cayman Limited
Jan. 31, 2008
Intrinsiq Materials Cayman Limited
Jun. 30, 2012
Bausch and Lomb
Jun. 30, 2011
Bausch and Lomb
Jun. 30, 2010
Bausch and Lomb
Collaborative Agreements And Contracts [Line Items]                                              
Consideration received in cash       $ 12,000,000   $ 12,000,000     $ 1,200,000.0       $ 10,050,000 $ 10,050,000                  
Accrued development cost liabilities       5,700,000   5,700,000                                  
Conditional note received       15,000,000                                      
Milestone payment upon FDA approval 25,000,000     25,000,000                                      
Share in future profits           50.00%                                  
Percentage of decrease in share of future profits           20.00%                                  
Pre-profitability net losses percentage           20.00%                                  
Percentage of royalties           20.00%                                  
Percentage of non-royalty consideration received           33.00%                                  
Deferred revenue         18,300,000               7,750,000 7,750,000                  
Period of revenue recognized from the effective date of agreement         21.5                                    
Revenue related to agreement           111,000.0 192,000.0 22,300,000                              
Research Funding                     500,000 500,000                      
Upfront payment                     2,300,000     2,300,000                  
License option right                     20,000,000                        
Development and sales performance milestone maximum                     146,500,000                        
Collaborative research and development revenue   3,300,000               754,000.0 3.3   3,300,000       1,100,000 83,000 121,000        
Collaborative research and development revenue                     6,700,000                        
Collaborative research and development revenue over the expected performance period                     3 years 6 months                        
Obligated aggregate minimum royalties to be paid                                       3,550,000      
Royalties 1,446,000 1,353,000 483,000                         450,000         1,446,000 1,353,000 483,000
Period of revenue recognized from the effective date of agreement 17                                            
Capital equipment assets 405,000 133,000 15,000                       223,000                
Additional royalty income                                             1,200,000
Accounts receivable                                         $ 442,000 $ 290,000